about
Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptidesLipid-protein interactions: biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conservedAn efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinomaInvariant NKT cells sustain specific B cell responses and memory.Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.A novel self-lipid antigen targets human T cells against CD1c(+) leukemiasIntracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activationFine tuning by human CD1e of lipid-specific immune responses.A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse ModelInvariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation.CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolutionTargeted inactivation of the COP9 signalosome impairs multiple stages of T cell development.Follicular helper NKT cells induce limited B cell responses and germinal center formation in the absence of CD4(+) T cell help.Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells.miR-17∼92 family clusters control iNKT cell ontogenesis via modulation of TGF-β signaling.On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies.iNKT-cell help to B cells: a cooperative job between innate and adaptive immune responses.Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer.The T cell receptor alpha beta V-J shuffling shows lack of autonomy between the combining site and the constant domain of the receptor chains.Group 1 CD1-restricted T cells and the pathophysiological implications of self-lipid antigen recognition.Of self-lipids, CD1-restricted T cells, and contact sensitization.Harnessing the CD1 restricted T cell response for leukemia adoptive immunotherapy.The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.Targeting leukemia by CD1c-restricted T cells specific for a novel lipid antigen.Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop.Dual receptor T-cells. Implications for alloreactivity and autoimmunity.T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genesEditing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer.In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.T cell receptor heterogeneity in gamma delta T cell clones from intestinal biopsies of patients with celiac disease.The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function.Functional education of invariant NKT cells by dendritic cell tuning of SHP-1.Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.CD1d-restricted help to B cells by human invariant natural killer T lymphocytes.Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.Vascular attack and immunotherapy: a 'two hits' approach to improve biological treatment of cancer.Use of MHC class II tetramers to investigate CD4+ T cell responses: problems and solutions.
P50
Q25257170-79DE7CC4-FE06-4C5C-AD85-F925B6C95106Q28592914-B94E01B7-B237-4AA0-9E1E-23F4199E8280Q28749871-C83F1349-1A11-4B19-A706-FDCA4716A334Q30479030-EA684980-46EB-4692-AEA4-5CE803CD68F1Q33318487-EF67A5D8-65C3-4CEC-99D2-31D40508D813Q33523809-F03DAE59-67BE-4E31-94A4-07FFE567FD04Q33826848-AAC60F7F-7BCB-4334-8654-ECA98A7B6E1EQ35037006-4D3A0046-0F5C-4336-BB64-4C717D8DFBBFQ35180802-0309EC7C-9581-4A39-9BFE-824ABF5A4CAEQ35931493-D2BA1B51-0E76-4C45-B52F-5D2B42DFF1CCQ36057428-178CAB65-6477-4E25-A6A6-8C5B54F95ABEQ36404242-F903AF1F-44F6-4877-8C9E-FDEFCE6B8ADEQ36502887-363D6D91-CA32-4282-AF21-BC24CA4624B4Q36573926-10736E20-B6D1-4E1D-BF0D-BD9442F85D3EQ36702144-29D659A5-2786-4D88-BE8F-5998EA051C27Q37534350-B56FC5FF-CF19-4EDB-9FBC-39248FBA89F8Q37824066-DAB8C1EF-5755-4AE8-95A6-44911942771CQ38208261-E5402569-57D4-4AEA-98C5-F90F95261E84Q38244094-2B2EC9CC-8199-4D40-80F4-E12D046481B0Q38322044-CBD533E5-8F39-4494-B65A-F526A00732EBQ38619546-8516767A-AD22-46F0-A212-6DA0DBC068DCQ38687053-19DE2957-F963-4F23-AD89-FE93B8C04125Q39437723-C561462A-200C-4179-A25F-3C0A1EF088AEQ39725034-EE4E93F5-02A6-494D-A4C4-43348FA806F3Q39835296-897B9FE2-E400-4E2F-AE91-E754F9241845Q40229112-51A5219E-C773-4765-822F-03F9226D4EADQ40364593-EE4ECB37-5F31-4A76-AF3E-C912AC07958EQ40465770-B3E9CCD3-5091-4AA9-B334-ED5DB64A1D4CQ40866158-A4FF4F2F-2ACD-41FA-922F-62C5967BAD36Q41069577-7DFB03DE-F4AC-4F9D-90CF-B834F93765F5Q41434481-C356E70E-1925-4F3A-B8F4-446FBF00A2FFQ41575399-D677058C-805F-4F0F-8EB9-6A99256334BFQ42068252-0AD3EB73-3C92-49DD-92EA-8B55E40842C6Q42274162-FA485A59-6E86-4CEA-B5B9-E0385FF1CE01Q42595560-9F54CC3C-7579-41F2-80B8-9BAB0DD2C961Q42944844-01D26227-2922-4204-A5B8-D562AB09EBA0Q43976641-A205994E-3B2C-439A-AD20-FECD14A65A7DQ45241828-FC2900F8-3938-4E1D-BE3A-992FAEF4DCF9Q45859702-AE605E45-1F00-4FA5-8942-1090C81CD111Q45878801-C5E1C659-C4E5-48D7-A942-67768B97141D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giulia Casorati
@ast
Giulia Casorati
@en
Giulia Casorati
@es
Giulia Casorati
@nl
Giulia Casorati
@sl
type
label
Giulia Casorati
@ast
Giulia Casorati
@en
Giulia Casorati
@es
Giulia Casorati
@nl
Giulia Casorati
@sl
prefLabel
Giulia Casorati
@ast
Giulia Casorati
@en
Giulia Casorati
@es
Giulia Casorati
@nl
Giulia Casorati
@sl
P106
P1153
7005023144
P21
P31
P496
0000-0002-5102-4112